Cytiva has acquired CEVEC Pharmaceuticals, a German provider of high-performance cell line development and viral vector manufacturing technologies, further strengthening Cytiva’s biomanufacturing services.
 
The acquisition aims to address industry challenges in cell and gene therapy in establishing production processes to keep up with the increasing demand for volume and consistent quality of viral vectors. With its scalable producer cell lines for vectors based on Adeno- Associated Virus (AAV) and Adenovirus, CEVEC covers two of the most widely used vectors for delivering therapeutic genes to target cells and tissues.
 
Producer Cell Lines (PCLs) as enabled by CEVEC’s ELEVECTA Technology enable yield, scalability, and robustness in the manufacturing process. With the ELEVECTA Technology, all components necessary for vector production are stably integrated into the genome of the PCL, offering an alternative to technologies based on transfection or the use of a helper virus.
 
CEVEC and its 46 scientific experts will become part of Cytiva, and its products, services and technologies will continue to be offered under the ELEVECTA and CAP brands.
 
Emmanuel Abate, President, Genomic Medicine at Cytiva, said, “Cevec’s innovative technology complements Cytiva’s offering and brings the promise of improved viral vector manufacturing. With Cytiva’s global reach and ability to scale, more customers will have access to Cevec’s technology and expertise to help accelerate and advance therapeutics for the benefit of patients.”
 
Dr. Nicole Faust, CEO of CEVEC Pharmaceuticals, said, “We are excited to become part of Cytiva. Combined with Cytiva’s global presence and leading brands, this enables the whole gene therapy industry to embark on new and powerful solutions for scalable vector manufacturing and start a new era for therapies made available to patients in need.”